SCHEMBL30766008

SCHEMBL30766008

C[C@@H](Nc1cnc(N2CCN(C(=O)OC(C)(C)C)CC2)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.43
KIT P10721 2/20 0.39
CKS1B P61024 2/20 0.39
SKP1 P63208 2/20 0.39
SKP2 Q13309 2/20 0.39
P2RX3 P56373 1/20 0.39
DTYMK P23919 2/20 0.37
ALK Q9UM73 1/20 0.37
ACHE P22303 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
NR2F2 P24468 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM1A O60341 1/20 0.36
PTPN11 Q06124 1/20 0.36
PIK3CA P42336 1/20 0.36
GBA1 P04062 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558461 0.94 BACE1 (0.43) BACE1KITCKS1BSKP1SKP2
SCHEMBL30765863 0.88 GAA (0.38) LMNAHTTSMN1; SMN2PIK3CA
SCHEMBL30766002 0.86 USP2 (0.37) BACE1ALKLMNAHTTPIK3CA
SCHEMBL30765755 0.86 BACE1 (0.37) BACE1P2RX3ALK
SCHEMBL30765691 0.80 CYP8B1 (0.35) PIK3CA
SCHEMBL30765814 0.79 LMNA (0.39) LMNAHTTSMN1; SMN2
SCHEMBL30765619 0.79 LMNA (0.38) NPC1LMNAHTTSMN1; SMN2
SCHEMBL30765991 0.79 ELANE (0.42) LMNA
SCHEMBL30765957 0.78 ALDH1A1 (0.38) P2RX3LMNA
SCHEMBL30765710 0.78 LMNA (0.38) P2RX3NPC1LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed